HC Wainwright Increases Earnings Estimates for Genmab A/S

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Stock analysts at HC Wainwright increased their FY2025 EPS estimates for Genmab A/S in a research note issued to investors on Wednesday, January 28th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $2.00 per share for the year, up from their prior estimate of $1.89. HC Wainwright has a “Buy” rating and a $39.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S’s Q1 2026 earnings at $0.27 EPS, Q2 2026 earnings at $0.49 EPS and Q3 2026 earnings at $0.47 EPS.

Other equities analysts have also recently issued research reports about the company. Johnson Rice reaffirmed a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Truist Financial reaffirmed a “buy” rating and issued a $48.00 target price (down from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Zacks Research lowered shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Finally, Wall Street Zen raised shares of Genmab A/S from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Genmab A/S currently has an average rating of “Moderate Buy” and a consensus target price of $39.25.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $33.35 on Thursday. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $35.43. The stock has a market cap of $21.42 billion, a PE ratio of 14.19, a PEG ratio of 18.54 and a beta of 0.90. The firm has a 50-day simple moving average of $32.42 and a 200 day simple moving average of $28.97.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $975.40 million.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in shares of Genmab A/S by 17.0% in the second quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock valued at $19,282,000 after buying an additional 135,814 shares in the last quarter. Squarepoint Ops LLC grew its holdings in Genmab A/S by 636.3% during the 2nd quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock worth $1,947,000 after acquiring an additional 81,434 shares during the last quarter. Eagle Global Advisors LLC increased its position in Genmab A/S by 16.3% in the 3rd quarter. Eagle Global Advisors LLC now owns 244,470 shares of the company’s stock valued at $7,498,000 after acquiring an additional 34,175 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Genmab A/S in the second quarter worth about $257,000. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of Genmab A/S by 152.3% in the second quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock worth $71,367,000 after acquiring an additional 2,084,966 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

Key Stories Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and $39 price target on GMAB, implying roughly mid-teens upside from current levels — supportive of investor demand. H.C. Wainwright Reiterates Buy Rating on Genmab AS (GMAB)
• Positive Sentiment: HC Wainwright raised its FY2025 EPS projection to $2.00 (from $1.89), signaling higher expected full-year profitability that can support valuation. HC Wainwright / Marketbeat
• Neutral Sentiment: Genmab granted 32,806 restricted stock units and 34,307 warrants to employees. The award is standard compensation-related dilution but is very small relative to the company’s outstanding shares, so impact is likely minimal. Grant of Restricted Stock Units and Warrants to Employees in Genmab
• Neutral Sentiment: Reported short-interest data for January appear anomalous (showing 0 shares / NaN change) and are inconclusive — not a reliable signal of bearish pressure at this time.
• Negative Sentiment: HC Wainwright cut near-term quarterly EPS forecasts (Q1 → $0.27 from $0.34; Q2 → $0.49 from $0.58; Q3 → $0.47 from $0.59), which reduces near-term earnings expectations and could weigh on sentiment if investors focus on short-term performance. HC Wainwright / Marketbeat

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.